ClinicalTrials.gg
TerminatedNCT00138671Updated Feb 2, 2010Results posted

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

A Phase 3 interventional study of Subcutaneous Insulin and Inhaled Insulin in Diabetes Mellitus and Chronic Obstructive Pulmonary Disease, sponsored by Pfizer. Terminated at 88 sites in 5 countries. Open to participants aged 30 Years to 77 Years. Per ClinicalTrials.gov, last updated 2010-02-02.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
30 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus — 1 open to participants now, 2 under way, none of them phase 3. Insulin · Diabetes Mellitus.

Enrollment
21st of 49
105 · median 74
Started
2003
with 3 others
Phase 3
11 of 51
none open now
Registered
5th of 51
by date
Lead sponsor
5 of 51
Pfizer

Among the 51 studies testing insulin in Diabetes Mellitus, this one is the 21st largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2003, is one of 11 in phase 3, and was the 5th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 51 studies testing insulin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 30 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, or all of them as a file.
02

Study summary

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.

Read the detailed description

Pfizer announced in October 2007 that it would stop marketing Exubera. At that time recruitment for study A2171030 was placed on hold. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171030 was terminated on June 17, 2008. Neither safety nor efficacy reasons were the cause of the study termination.

03

Conditions studied

  • Diabetes Mellitus
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
30 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes Mellitus (Type 1 or Type 2) currently controlled with injected insulin
  • Prior smokers with a fixed airflow obstruction at screening (/FVC \< 70%) and FEV1 \< 80% predicted and/or a history of chronic productive cough.

Exclusion criteria

Exclusion Criteria:

  • Poorly controlled, unstable or -dependent , insulin pump therapy, active smoking
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    Subcutaneous Insulin

    Drug: Subcutaneous Insulin

  • Experimental
    Inhaled Insulin

    Drug: Inhaled Insulin

Interventions

  • Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.

  • Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 was measured in liters (L) 30 minutes following the administration of ipratropium. Change from baseline: mean of (value of observed FEV1 (L) at treatment duration minus baseline value).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52

  2. Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco)

    DLco measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of ipratropium. Change from baseline: mean of (value of observed DLco (mL/min/mmHg) at treatment duration minus baseline value).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52

Secondary outcomes

  1. Full Pulmonary Function Tests (PFTs) (Spirometry, Pre-Ipratropium and Pre-Insulin PFTs)

    Full PFTs included spirometry pre- and 30-minutes post-ipratropium and were completed between the hours of 6 AM and 10 AM with subjects in the fasting state. Full PFT data were collected, but not analyzed.

    Time frame: Duration of the study

  2. Full PFTs (DLco, Pre-Ipratropium and Pre- Insulin PFTs)

    Full PFTs included DLco pre- and 30-minutes post-ipratropium and were completed between the hours of 6 AM and 10 AM with subjects in the fasting state. Full PFT data were collected, but not analyzed.

    Time frame: Duration of the study

  3. Other PFTs (Besides FEV1 and DLco)

    Other PFTs (besides FEV1 and DLco) were measured 30 minutes following the administration of ipratropium. Other PFTs included forced vital capacity (FVC), peak expiratory flow rate (maximal forced expiratory flow) (PEFR\[FEFmax\]), and forced expiratory flow from 25% to 75% of vital capacity (FEF25%-75%). Other PFT data were collected, but not analyzed.

    Time frame: Duration of the study

  4. Bronchodilator Responsiveness as Determined by the Change in FEV1

    Responsiveness was the percent change from the FEV1 value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as \[(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1\] multiplied by 100.

    Time frame: Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52

  5. Insulin Dose Responsiveness for FEV1

    FEV1 dose responsiveness 10 and 60 minutes after insulin. FEV1 dose-responsiveness to insulin (defined as the difference between the FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post-dose FEV1 value minus pre-dose FEV1 value).

    Time frame: Baseline, Week 9, Week 51

  6. Insulin Dose Responsiveness for DLco

    DLco dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin (defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value).

    Time frame: Baseline, Week 9, Week 51

  7. Methacholine PC20

    Methacholine challenge testing was conducted at selected sites at visits which did not occur at other sites (Weeks -2.9, -0.9, 11, 50 and 52+5). Methacholine challenge was not analyzed as there was only 1 test performed, which was a baseline test, and no methacholine tests performed in subjects using inhaled insulin.

    Time frame: Duration of the study

  8. Mean Weekly Number of Puffs of Short-Acting Bronchodilator Used

    All subjects used diary cards to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol plus ipratropium plus Combivent®, as applicable) daily, immediately upon arising, and again in the evening or before bed. Mean weekly number of puffs of short-acting bronchodilator used data were collected, but not analyzed.

    Time frame: Duration of the study

  9. Incidence of Non-Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

    Non-severe COPD exacerbation = additional therapy (systemic corticosteroids, antibiotics, oxygen) needed for worsening respiratory symptoms and/or lung function, not needing hospitalization \> 24 hours. Crude event rate = total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.

    Time frame: 0 to 1 week to > 9 months

  10. Incidence of Severe COPD Exacerbations

    Severe COPD exacerbation = a COPD-related hospitalization \> 24 hours. Crude event rate = total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.

    Time frame: 0 to 1 week to > 9 months

  11. Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) Questionnaires

    The BDI and TDI measured or quantitated the severity of breathlessness (shortness of breath) in symptomatic subjects. BDI and TDI data were collected, but not analyzed.

    Time frame: Duration of the study

  12. Change From Baseline in Glycosylated Hemoglobin (HbA1c)

    Change from baseline: mean of (value of observed HbA1c at treatment duration minus baseline value).

    Time frame: Baseline, Weeks 6, 12, 26, 39, and 52

  13. Change From Baseline in Fasting Plasma Glucose

    Change from baseline: mean of (value of observed fasting plasma glucose in milligrams/deciliters (mg/dL) at treatment duration minus baseline value).

    Time frame: Baseline, Weeks 6, 12, 26, 39, 52

  14. Change From Baseline in Body Weight

    Change from baseline: mean of (value of observed body weight in kilograms (kg) at treatment duration minus baseline value).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 6, 9, 11, 12, 18, 26, 39, 50, 51, 52

  15. Mean Total Daily Intermediate-/Long-Acting Insulin Dose (Unadjusted for Body Weight)

    Intermediate-/long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups.

    Time frame: Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52

  16. Mean Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)

    Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

    Time frame: Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52

  17. Mean Total Daily Intermediate-/Long-Acting Insulin Dose (Adjusted for Body Weight)

    Intermediate/long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Dose was adjusted for body weight (units divided by kg).

    Time frame: Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52

  18. Mean Total Daily Short-Acting Insulin Dose (Adjusted for Body Weight)

    Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin. Dose was adjusted for body weight (mg divided by kg or units divided by kg).

    Time frame: Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52

  19. Lipids

    Lipids collected: Total cholesterol, high-density lipoprotein, low-density lipoptrotein, and triglycerides. Lipids data were collected, but not analyzed.

    Time frame: Duration of the study

  20. Hypoglycemic Event Rates

    A hypoglycemic event was identified by characteristic symptoms; blood glucose levels at 59 mg/dL (3.2 mmol/L) or less with a glucose check; or any glucose measurement 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate=total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.

    Time frame: 0 to1 month to > 11 months

  21. Severe Hypoglcyemic Event Rates

    An event was severe if the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL or the blood glucose was not measured, but the clinical manifestations were reversed by oral carbohydrates, subcutaneous glucagon, or intravenous glucose. Crude event rate=total events/100 subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.

    Time frame: 0 to 1 month to > 11 months

07

Results

Posted Nov 13, 2009
Limitations and caveats
This study was terminated due to Pfizer's decision to stop marketing Exubera®. Due to inconsistency in concomitant medication data entry, interpretation of the event rates for non-severe exacerbations may be of limited clinical value.

Participant flow

Participant flow — Overall Study
MilestoneInhaled InsulinSubcutaneous Insulin
Started5946
Completed4630
Not completed1316
Withdrew: Death03
Withdrew: Adverse event63
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject35
Withdrew: Other33

Outcome measures

PrimaryChange From Baseline in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

FEV1 was measured in liters (L) 30 minutes following the administration of ipratropium. Change from baseline: mean of (value of observed FEV1 (L) at treatment duration minus baseline value).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52
Reported as:
Mean · L
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
LInhaled InsulinSubcutaneous Insulin
Week 1 (n=52, 39)-0.021 ± 0.132-0.018 ± 0.125
Week 2 (n=51, 40)-0.039 ± 0.116-0.042 ± 0.120
Week 3 (n=47, 40)-0.026 ± 0.121-0.048 ± 0.145
Week 4 (n=50, 38)-0.050 ± 0.140-0.039 ± 0.151
Week 6 (n=53, 38)-0.045 ± 0.152-0.070 ± 0.165
Week 12 (n=48, 41)-0.056 ± 0.180-0.007 ± 0.187
Week 18 (n=52, 37)-0.049 ± 0.158-0.071 ± 0.195
Week 26 (n=52, 38)-0.067 ± 0.174-0.096 ± 0.189
Week 39, (n=47, 34)-0.053 ± 0.174-0.092 ± 0.232
Week 52 (n=45, 30)-0.068 ± 0.208-0.128 ± 0.184
SecondaryFull Pulmonary Function Tests (PFTs) (Spirometry, Pre-Ipratropium and Pre-Insulin PFTs)

Full PFTs included spirometry pre- and 30-minutes post-ipratropium and were completed between the hours of 6 AM and 10 AM with subjects in the fasting state. Full PFT data were collected, but not analyzed.

Time frame:
Duration of the study
Reported as:
Number · L

No measurements were reported for this outcome.

SecondaryFull PFTs (DLco, Pre-Ipratropium and Pre- Insulin PFTs)

Full PFTs included DLco pre- and 30-minutes post-ipratropium and were completed between the hours of 6 AM and 10 AM with subjects in the fasting state. Full PFT data were collected, but not analyzed.

Time frame:
Duration of the study
Reported as:
Number · mL/min/mmHg

No measurements were reported for this outcome.

PrimaryChange From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco)

DLco measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of ipratropium. Change from baseline: mean of (value of observed DLco (mL/min/mmHg) at treatment duration minus baseline value).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52
Reported as:
Mean · mL/min/mmHg
Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusion Capacity (DLco)
mL/min/mmHgInhaled InsulinSubcutaneous Insulin
Week 1 (n=51, 40)-0.263 ± 1.610-0.319 ± 0.984
Week 2 (n=51, 40)-0.491 ± 1.288-0.031 ± 1.106
Week 3 (n=47, 40)-0.494 ± 1.1750.169 ± 1.303
Week 4 (n=50, 39)-0.640 ± 1.345-0.482 ± 1.321
Week 6 (n=52, 38)-0.625 ± 1.356-0.576 ± 1.226
Week 12 (n=47, 40)-0.379 ± 1.516-0.534 ± 1.506
Week 18 (n=51, 36)-0.287 ± 1.463-0.286 ± 1.796
Week 26 (n=52, 38)-0.287 ± 1.841-0.947 ± 1.643
Week 39 (n=47, 33)-0.611 ± 1.475-0.891 ± 2.137
Week 52 (n=45, 29)-0.614 ± 1.754-0.882 ± 1.720
SecondaryOther PFTs (Besides FEV1 and DLco)

Other PFTs (besides FEV1 and DLco) were measured 30 minutes following the administration of ipratropium. Other PFTs included forced vital capacity (FVC), peak expiratory flow rate (maximal forced expiratory flow) (PEFR\[FEFmax\]), and forced expiratory flow from 25% to 75% of vital capacity (FEF25%-75%). Other PFT data were collected, but not analyzed.

Time frame:
Duration of the study
Reported as:
Number · mL

No measurements were reported for this outcome.

SecondaryBronchodilator Responsiveness as Determined by the Change in FEV1

Responsiveness was the percent change from the FEV1 value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as \[(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1\] multiplied by 100.

Time frame:
Weeks 1, 2, 3, 4, 6, 12, 18, 26, 39, 52
Reported as:
Mean · percent change
Bronchodilator Responsiveness as Determined by the Change in FEV1
percent changeInhaled InsulinSubcutaneous Insulin
Week 1 (n=52, 39)4.890 ± 5.7275.693 ± 7.249
Week 2 (n=51, 40)6.132 ± 6.2005.245 ± 6.254
Week 3 (n=47, 40)6.346 ± 7.4695.820 ± 8.347
Week 4 (n=50, 38)5.177 ± 7.2116.382 ± 9.685
Week 6 (n=53, 38)5.988 ± 6.0347.736 ± 10.139
Week 12 (n=48, 41)6.473 ± 8.9945.542 ± 6.791
Week 18 (n=52, 37)6.700 ± 6.0205.152 ± 8.155
Week 26 (n=52, 38)5.585 ± 5.5925.856 ± 8.562
Week 39 (n=47, 34)6.634 ± 5.8296.098 ± 9.311
Week 52 (n=45, 30)6.030 ± 4.7005.445 ± 8.390
SecondaryInsulin Dose Responsiveness for FEV1

FEV1 dose responsiveness 10 and 60 minutes after insulin. FEV1 dose-responsiveness to insulin (defined as the difference between the FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post-dose FEV1 value minus pre-dose FEV1 value).

Time frame:
Baseline, Week 9, Week 51
Reported as:
Mean · L
Insulin Dose Responsiveness for FEV1
LInhaled InsulinSubcutaneous Insulin
Baseline, 10 minutes (n=50, 39)0.009 ± 0.0760.022 ± 0.106
Baseline, 60 minutes (n=50, 39)-0.004 ± 0.0960.020 ± 0.127
Week 9, 10 minutes (n=42, 31)-0.004 ± 0.1100.016 ± 0.096
Week 9, 60 minutes (n=42, 30)0.011 ± 0.1090.030 ± 0.116
Week 51, 10 minutes (n=46, 31)-0.021 ± 0.121-0.002 ± 0.084
Week 51, 60 minutes (n=45, 31)0.005 ± 0.115-0.020 ± 0.141
SecondaryInsulin Dose Responsiveness for DLco

DLco dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin (defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value).

Time frame:
Baseline, Week 9, Week 51
Reported as:
Mean · mL/min/mmHg
Insulin Dose Responsiveness for DLco
mL/min/mmHgInhaled InsulinSubcutaneous Insulin
Baseline, 10 minutes (n=48, 39)-0.461 ± 1.157-0.195 ± 0.707
Baseline, 60 minutes (n=49, 39)-0.597 ± 1.102-0.160 ± 1.217
Week 9, 10 minutes (n=41, 30)-0.182 ± 1.015-0.238 ± 1.505
Week 9, 60 minutes (n=42, 29)0.013 ± 2.288-0.373 ± 1.574
Week 51, 10 minutes (n=44, 31)-0.465 ± 0.7810.054 ± 1.204
Week 51, 60 minutes (n=44, 31)-0.395 ± 0.885-0.163 ± 1.211
SecondaryMethacholine PC20

Methacholine challenge testing was conducted at selected sites at visits which did not occur at other sites (Weeks -2.9, -0.9, 11, 50 and 52+5). Methacholine challenge was not analyzed as there was only 1 test performed, which was a baseline test, and no methacholine tests performed in subjects using inhaled insulin.

Time frame:
Duration of the study
Reported as:
Number · mg/mL

No measurements were reported for this outcome.

SecondaryMean Weekly Number of Puffs of Short-Acting Bronchodilator Used

All subjects used diary cards to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol plus ipratropium plus Combivent®, as applicable) daily, immediately upon arising, and again in the evening or before bed. Mean weekly number of puffs of short-acting bronchodilator used data were collected, but not analyzed.

Time frame:
Duration of the study
Reported as:
Number · puffs

No measurements were reported for this outcome.

SecondaryIncidence of Non-Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Non-severe COPD exacerbation = additional therapy (systemic corticosteroids, antibiotics, oxygen) needed for worsening respiratory symptoms and/or lung function, not needing hospitalization \> 24 hours. Crude event rate = total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.

Time frame:
0 to 1 week to > 9 months
Reported as:
Number · events/subject-month (crude event rate)
Incidence of Non-Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
events/subject-month (crude event rate)Inhaled InsulinSubcutaneous Insulin
0 to 1 week (n=59, 43)0.000.00
> 1 to 2 weeks (n=59, 43)0.070.00
> 2 to 3 weeks (n=59, 43)0.000.00
> 3 to 4 weeks (n=59, 42)0.070.10
> 4 to 6 weeks (n=57, 42)0.080.05
> 6 to 9 weeks (n=56, 42)0.050.03
> 9 to 12 weeks (n=55, 41)0.050.07
> 3 to 6 months (n=52, 41)0.020.01
> 6 to 9 months (n=52, 37)0.010.01
> 9 months (n=50, 35)0.010.02
Overall (n=59, 43)0.020.02
SecondaryIncidence of Severe COPD Exacerbations

Severe COPD exacerbation = a COPD-related hospitalization \> 24 hours. Crude event rate = total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.

Time frame:
0 to 1 week to > 9 months
Reported as:
Number · events/subject-month (crude event rate)
Incidence of Severe COPD Exacerbations
events/subject-month (crude event rate)Inhaled InsulinSubcutaneous Insulin
0 to 1 week (n=59, 43)0.000.00
> 1 to 2 weeks (n=59, 43)0.000.00
> 2 to 3 weeks (n=59, 43)0.000.00
> 3 to 4 weeks (n=59, 42)0.000.00
> 4 to 6 weeks (n=57, 42)0.000.00
> 6 to 9 weeks (n=56, 42)0.000.00
> 9 to 12 weeks (n=55, 41)0.000.00
> 3 to 6 months (n=52, 41)0.000.00
> 6 to 9 months (n=52, 37)0.010.00
> 9 months (n=50, 35)0.000.00
Overall (n= 59, 43)0.000.00
SecondaryBaseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) Questionnaires

The BDI and TDI measured or quantitated the severity of breathlessness (shortness of breath) in symptomatic subjects. BDI and TDI data were collected, but not analyzed.

Time frame:
Duration of the study
Reported as:
Number · grade

No measurements were reported for this outcome.

SecondaryChange From Baseline in Glycosylated Hemoglobin (HbA1c)

Change from baseline: mean of (value of observed HbA1c at treatment duration minus baseline value).

Time frame:
Baseline, Weeks 6, 12, 26, 39, and 52
Reported as:
Mean · percent
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
percentInhaled InsulinSubcutaneous Insulin
Week 6 (n=56, 40)-0.40 ± 0.81-0.48 ± 0.60
Week 12 (n=50, 41)-0.53 ± 0.98-0.42 ± 0.65
Week 26 (n=52, 38)-0.39 ± 0.96-0.32 ± 0.79
Week 39 (n=48, 35)-0.34 ± 1.11-0.20 ± 1.01
Week 52 (n=46, 32)-0.30 ± 1.10-0.23 ± 0.84
Week 52 LOCF (n=57, 43)-0.28 ± 1.03-0.26 ± 0.79
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.10 · 90% CI -0.17 to 0.36
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -0.01 · 90% CI -0.27 to 0.26
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -0.02 · 90% CI -0.29 to 0.26
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -0.08 · 90% CI -0.36 to 0.20
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.06 · 90% CI -0.23 to 0.35
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.01 · 90% CI -0.29 to 0.31
SecondaryChange From Baseline in Fasting Plasma Glucose

Change from baseline: mean of (value of observed fasting plasma glucose in milligrams/deciliters (mg/dL) at treatment duration minus baseline value).

Time frame:
Baseline, Weeks 6, 12, 26, 39, 52
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose
mg/dLInhaled InsulinSubcutaneous Insulin
Week 6 (n=52, 39)-24.67 ± 69.692.89 ± 41.17
Week 12 (n=48, 39)-30.73 ± 52.99-0.18 ± 46.25
Week 26 (n=47, 38)-34.92 ± 61.6310.45 ± 62.80
Week 39 (n=47, 33)-20.45 ± 56.6210.43 ± 98.53
Week 52 (n=45, 31)-23.40 ± 65.7712.37 ± 58.01
Week 52 (LOCF) (n=57, 43)-28.55 ± 65.852.36 ± 66.51
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -4.475 · 90% CI -23.47 to 14.518
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -10.91 · 90% CI -30.04 to 8.232
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -22.84 · 90% CI -42.51 to -3.166
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -8.222 · 90% CI -28.52 to 12.075
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -8.329 · 90% CI -29.27 to 12.616
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 1.406 · 90% CI -13.70 to 16.514
SecondaryChange From Baseline in Body Weight

Change from baseline: mean of (value of observed body weight in kilograms (kg) at treatment duration minus baseline value).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 6, 9, 11, 12, 18, 26, 39, 50, 51, 52
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgInhaled InsulinSubcutaneous Insulin
Week 1 (n=52, 40)0.25 ± 1.620.02 ± 0.98
Week 2 (n=51, 40)0.26 ± 1.770.15 ± 1.73
Week 3 (n=49, 41)0.19 ± 2.030.13 ± 1.90
Week 4 (n=53, 41)0.19 ± 1.980.24 ± 2.13
Week 6 (n=54, 39)0.42 ± 2.260.26 ± 1.94
Week 9 (n=47, 34)0.31 ± 2.930.25 ± 2.31
Week 11 (n=8, 8)0.03 ± 2.25-0.14 ± 2.97
Week 12 (n=49, 41)0.42 ± 3.290.34 ± 3.69
Week 18 (n=52, 37)0.40 ± 3.660.90 ± 4.01
Week 26 (n=52, 38)0.85 ± 3.951.99 ± 4.03
Week 39 (n=47, 34)0.61 ± 4.372.43 ± 5.21
Week 50 (n=8, 6)1.75 ± 4.906.33 ± 9.06
Week 51 (n=23, 17)1.21 ± 4.822.67 ± 3.28
Week 52 (n=43, 27)0.97 ± 5.653.32 ± 4.68
Week 52 LOCF (n=59, 43)0.99 ± 4.202.40 ± 4.79
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.884 · 90% CI -0.317 to 2.084
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.470 · 90% CI -0.728 to 1.668
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.382 · 90% CI -0.815 to 1.579
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.405 · 90% CI -0.793 to 1.602
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.562 · 90% CI -0.642 to 1.766
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.416 · 90% CI -0.809 to 1.641
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.019 · 90% CI -1.416 to 1.454
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): 0.091 · 90% CI -1.127 to 1.308
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -0.309 · 90% CI -1.551 to 0.934
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -0.869 · 90% CI -2.123 to 0.384
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -1.664 · 90% CI -2.968 to -0.360
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -2.116 · 90% CI -3.829 to -0.403
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -1.801 · 90% CI -3.204 to -0.397
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -2.026 · 90% CI -3.384 to -0.668
  • Inhaled Insulin vs Subcutaneous Insulin · Mean difference (final values): -1.451 · 90% CI -3.003 to 0.101
SecondaryMean Total Daily Intermediate-/Long-Acting Insulin Dose (Unadjusted for Body Weight)

Intermediate-/long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups.

Time frame:
Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52
Reported as:
Mean · Units
Mean Total Daily Intermediate-/Long-Acting Insulin Dose (Unadjusted for Body Weight)
UnitsInhaled InsulinSubcutaneous Insulin
Week 1 (n=53, 40)43.78 ± 22.2048.18 ± 23.44
Week 2 (n=50, 41)44.96 ± 22.5048.04 ± 24.33
Week 3 (n=51, 39)47.04 ± 24.3650.53 ± 24.44
Week 4 (n=52, 41)47.50 ± 25.9450.30 ± 25.61
Week 6 (n=54, 40)49.56 ± 26.6151.34 ± 25.91
Week 9 (n=47, 35)48.68 ± 28.6156.72 ± 25.89
Week 12 (n=51, 41)49.23 ± 28.4652.32 ± 29.49
Week 18 (n=51, 40)50.87 ± 29.3253.83 ± 29.34
Week 26 (n=51, 38)50.47 ± 28.8355.78 ± 28.11
Week 39 (n=49, 35)49.99 ± 29.0053.10 ± 26.11
Week 52 (n=48, 34)50.66 ± 30.6353.39 ± 26.32
SecondaryMean Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)

Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

Time frame:
Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52
Reported as:
Mean · mg, Units
Mean Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)
mg, UnitsInhaled InsulinSubcutaneous Insulin
Week 1 (n=54, 40)12.34 ± 5.2632.74 ± 21.59
Week 2 (n=51, 41)13.03 ± 6.6332.08 ± 22.25
Week 3 (n=52, 39)14.10 ± 6.8932.88 ± 21.60
Week 4 (n=53, 41)14.17 ± 7.2831.85 ± 22.29
Week 6 (n=55, 40)15.17 ± 7.2033.42 ± 22.72
Week 9 (n=48, 35)15.82 ± 7.4136.65 ± 22.94
Week 12 (n=52, 41)15.64 ± 7.8033.58 ± 23.94
Week 18 (n=52, 40)16.47 ± 7.4835.36 ± 26.06
Week 26 (n=52, 38)16.71 ± 8.0537.73 ± 26.14
Week 39 (n=49, 35)17.22 ± 8.6037.47 ± 26.20
Week 52 (n=48, 34)16.85 ± 9.5239.28 ± 25.13
SecondaryMean Total Daily Intermediate-/Long-Acting Insulin Dose (Adjusted for Body Weight)

Intermediate/long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Dose was adjusted for body weight (units divided by kg).

Time frame:
Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52
Reported as:
Mean · Units/kg
Mean Total Daily Intermediate-/Long-Acting Insulin Dose (Adjusted for Body Weight)
Units/kgInhaled InsulinSubcutaneous Insulin
Week 1 (n=51, 40)0.46 ± 0.220.48 ± 0.19
Week 2 (n=50, 40)0.47 ± 0.220.48 ± 0.20
Week 3 (n=49, 39)0.50 ± 0.250.50 ± 0.21
Week 4 (n=50, 41)0.49 ± 0.260.50 ± 0.21
Week 6 (n=53, 39)0.52 ± 0.270.51 ± 0.21
Week 9 (n=46, 34)0.50 ± 0.290.57 ± 0.21
Week 12 (n=49, 41)0.51 ± 0.280.52 ± 0.24
Week 18 (n=51, 37)0.53 ± 0.290.55 ± 0.24
Week 26 (n=51, 38)0.52 ± 0.280.55 ± 0.22
Week 39 (n=47, 34)0.51 ± 0.270.54 ± 0.24
Week 52, (n=43, 27)0.52 ± 0.290.56 ± 0.21
SecondaryMean Total Daily Short-Acting Insulin Dose (Adjusted for Body Weight)

Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin. Dose was adjusted for body weight (mg divided by kg or units divided by kg).

Time frame:
Weeks 1, 2, 3, 4, 6, 9, 12, 18, 26, 39, 52
Reported as:
Mean · mg/kg, Units/kg
Mean Total Daily Short-Acting Insulin Dose (Adjusted for Body Weight)
mg/kg, Units/kgInhaled InsulinSubcutaneous Insulin
Week 1 (n=52, 40)0.13 ± 0.050.33 ± 0.21
Week 2 (n=51, 40)0.14 ± 0.060.33 ± 0.21
Week 3 (n=49, 39)0.15 ± 0.070.33 ± 0.22
Week 4 (n=51, 41)0.15 ± 0.070.32 ± 0.22
Week 6 (n=54, 39)0.16 ± 0.070.34 ± 0.22
Week 9 (n=47, 34)0.17 ± 0.070.36 ± 0.22
Week 12 (n=49, 41)0.17 ± 0.080.34 ± 0.23
Week 18 (n=52, 37)0.17 ± 0.080.37 ± 0.24
Week 26 (n=52, 38)0.18 ± 0.080.38 ± 0.24
Week 39 (n=47, 34)0.18 ± 0.080.38 ± 0.25
Week 52 (n=43, 27)0.18 ± 0.090.40 ± 0.25
SecondaryLipids

Lipids collected: Total cholesterol, high-density lipoprotein, low-density lipoptrotein, and triglycerides. Lipids data were collected, but not analyzed.

Time frame:
Duration of the study
Reported as:
Number · mg/dL

No measurements were reported for this outcome.

SecondaryHypoglycemic Event Rates

A hypoglycemic event was identified by characteristic symptoms; blood glucose levels at 59 mg/dL (3.2 mmol/L) or less with a glucose check; or any glucose measurement 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate=total events divided by subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.

Time frame:
0 to1 month to > 11 months
Reported as:
Number · events / subject-month
Hypoglycemic Event Rates
events / subject-monthInhaled InsulinSubcutaneous Insulin
0 to 1 month (n=57, 43)1.761.36
> 1 to 2 months (n=56, 42)1.250.98
> 2 to 3 months (n=55, 42)1.210.97
> 3 to 4 months (n=52, 41)0.870.67
> 4 to 5 months (n=52, 40)0.961.01
> 5 to 6 months (n=52, 38)0.691.13
> 6 to 7 months (n=52, 37)0.620.92
> 7 to 8 months (n=51, 36)0.670.75
> 8 to 9 months (n=51, 36)0.590.78
> 9 to 10 months (n=51, 36)0.500.52
> 10 to 11 months (n=49, 34)0.750.51
> 11 months (n=47, 33)0.620.26
Overall (n=57, 43)0.890.84
SecondarySevere Hypoglcyemic Event Rates

An event was severe if the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL or the blood glucose was not measured, but the clinical manifestations were reversed by oral carbohydrates, subcutaneous glucagon, or intravenous glucose. Crude event rate=total events/100 subject-months. Subject-months=elapsed number of months a subject was in the study in each time interval.

Time frame:
0 to 1 month to > 11 months
Reported as:
Number · events / 100 subject-months
Severe Hypoglcyemic Event Rates
events / 100 subject-monthsInhaled InsulinSubcutaneous Insulin
0 to 1 month (n=57, 43)1.712.35
> 1 to 2 months (n=56, 42)1.790.00
> 2 to 3 months (n=55, 42)0.000.00
> 3 to 4 months (n=52, 41)0.000.00
> 4 to 5 months (n=52, 40)0.000.00
> 5 to 6 months (n=52, 38)0.000.00
> 6 to 7 months (n=52, 37)0.000.00
> 7 to 8 months (n=51, 36)0.000.00
> 8 to 9 months (n=51, 36)1.960.00
> 9 to 10 months (n=51, 36)2.010.00
> 10 to 11 months (n=49, 34)0.000.00
> 11 months (n=47, 33)0.000.00
Overall (n=57, 43)0.640.22

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Insulin———
Subcutaneous Insulin———
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventInhaled InsulinSubcutaneous Insulin
Myocardial infarctionCardiac disorders1/593/46
PneumoniaInfections and infestations3/590/46
Coronary artery diseaseCardiac disorders0/592/46
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/590/46
Inguinal herniaGastrointestinal disorders0/591/46
Intestinal obstructionGastrointestinal disorders0/591/46
NauseaGastrointestinal disorders0/591/46
Vomiting projectileGastrointestinal disorders0/591/46
HypothermiaGeneral disorders0/591/46
Ill-defined disorderGeneral disorders0/591/46
Most frequent other events
Showing 10 of 42
Most frequent other events
EventInhaled InsulinSubcutaneous Insulin
HypoglycaemiaMetabolism and nutrition disorders40/5930/46
Upper respiratory tract infectionInfections and infestations12/596/46
HyperhidrosisSkin and subcutaneous tissue disorders7/599/46
NasopharyngitisInfections and infestations10/596/46
HeadacheNervous system disorders10/593/46
AstheniaGeneral disorders9/595/46
DizzinessNervous system disorders8/597/46
BronchitisInfections and infestations8/592/46
Oedema peripheralGeneral disorders5/596/46
ArthralgiaMusculoskeletal and connective tissue disorders7/592/46

Baseline characteristics

Age, Customized
Age, Customized(participants)Inhaled InsulinSubcutaneous InsulinTotal
36 to 45 years134
46 to 55 years10414
56 to 65 years202343
66 to 75 years271542
> 75 years112
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled InsulinSubcutaneous InsulinTotal
Female17926
Male423779
Primary Diagnosis (Diabetes Type I or II)
Primary Diagnosis (Diabetes Type I or II)(participants)Inhaled InsulinSubcutaneous InsulinTotal
Type I7613
Type II524092
08

Study locations

88 sites
  • Pfizer Investigational Site
    Glendale, Arizona 85306, United States
  • Pfizer Investigational Site
    Peoria, Arizona 85381, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85004, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85006, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85016, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85715, United States
  • Pfizer Investigational Site
    Jonesboro, Arkansas 72401, United States
  • Pfizer Investigational Site
    Searcy, Arkansas 72143, United States
  • Pfizer Investigational Site
    Berkeley, California 94705, United States
  • Pfizer Investigational Site
    Fresno, California 93720, United States
  • Pfizer Investigational Site
    Greenbrae, California 94904, United States
  • Pfizer Investigational Site
    Huntington Beach, California 92648, United States
  • Pfizer Investigational Site
    Los Angeles, California 90073, United States
  • Pfizer Investigational Site
    Riverside, California 92506, United States
  • Pfizer Investigational Site
    Tustin, California 92780, United States
  • Pfizer Investigational Site
    Denver, Colorado 80209, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Chiefland, Florida 32626, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33756, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33765, United States
  • Pfizer Investigational Site
    DeLand, Florida 32720, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32608, United States
  • Pfizer Investigational Site
    Lake City, Florida 32025, United States
  • Pfizer Investigational Site
    Melbourne, Florida 32901, United States
  • Pfizer Investigational Site
    Miami, Florida 33144, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33401, United States
  • Pfizer Investigational Site
    Winter Park, Florida 32789, United States
  • Pfizer Investigational Site
    Decatur, Georgia 30033, United States
  • Pfizer Investigational Site
    Honolulu, Hawaii 96813, United States
  • Pfizer Investigational Site
    Honululu, Hawaii 96814, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60607, United States
  • Pfizer Investigational Site
    Normal, Illinois 61761, United States
  • Pfizer Investigational Site
    Evansville, Indiana 47713-1227, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46250, United States
  • Pfizer Investigational Site
    Des Moines, Iowa 50314, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67203, United States
  • Pfizer Investigational Site
    Madisonville, Kentucky 42431, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70119, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01103, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01107, United States
  • Pfizer Investigational Site
    Waltham, Massachusetts 02453, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64106, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Butte, Montana 59701, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68105, United States
  • Pfizer Investigational Site
    Henderson, Nevada 89015, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89103, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89128, United States
  • Pfizer Investigational Site
    Albany, New York 12205, United States
  • Pfizer Investigational Site
    Albany, New York 12206, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45231, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45242, United States
  • Pfizer Investigational Site
    Toledo, Ohio 43608, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Pfizer Investigational Site
    Medford, Oregon 97504, United States
  • Pfizer Investigational Site
    Portland, Oregon 97219, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15243, United States
  • Pfizer Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Pfizer Investigational Site
    Spartanburg, South Carolina 29307, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77701, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77706, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78237, United States
  • Pfizer Investigational Site
    Fredericksburg, Virginia 22401, United States
  • Pfizer Investigational Site
    Fredericksburg, Virginia 22408, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23225, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23229, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23235, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23249, United States
  • Pfizer Investigational Site
    Spokane, Washington 99202, United States
  • Pfizer Investigational Site
    Spokane, Washington 99204, United States
  • Pfizer Investigational Site
    Huntington, West Virginia 25701, United States
  • Pfizer Investigational Site
    Madison, Wisconsin 53705, United States
  • Pfizer Investigational Site
    Porto Alegre, RS 90035-170, Brazil
  • Pfizer Investigational Site
    Campinas, SP 13083-900, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01244-030, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 04231-030, Brazil
  • Pfizer Investigational Site
    Edmonton, Alberta T5J 3N4, Canada
  • Pfizer Investigational Site
    Red Deer, Alberta T4N 6V7, Canada
  • Pfizer Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Pfizer Investigational Site
    San Jose, Costa Rica
  • Pfizer Investigational Site
    Neuss, 41460, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2005
First posted
Aug 30, 2005
Start
Jan 2003
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Nov 13, 2009
Last update
Feb 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00138671
Lead sponsor
Pfizer
First posted
Aug 30, 2005
Start date
Jan 2003
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Nov 13, 2009
Last update
Feb 2, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion